Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
AssigneeAnovent Pharmaceutical (U.S.), LLC
InventorsCai Gu Huang, Ning He
Life of this patent
Estimating the term…
Abstract
The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) active substances selected from umeclidinium bromide and vilanterol trifenatate; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative; and (e) a pharmacologically acceptable stabilizer; and optionally includes other pharmacologically acceptable additives.
Claims20
A liquid, propellant-free pharmaceutical formulation comprising:
- (a) umeclidinium bromide and vilanterol trifenatate;
- (b) a solvent;
- (c) a pharmacologically acceptable solubilizing agent,
- wherein the pH of the formulation ranges from about 2.5 to about 6.
A liquid, propellant-free pharmaceutical formulation comprising:
- an aqueous solution of:
- (a) umeclidinium bromide in an amount of about 2 mg/100 mL to about 1050 mg/100 mL of the formulation;
- (b) vilanterol trifenatate in an amount of about 1 mg/100 mL to about 550 mg/100 mL of the formulation;
- (c) sulfobutylether β-cyclodextrin (SBECD) in an amount of about 1 g/100 mL to about 40 g/100 mL of the formulation;
- (d) sodium chloride in an amount of about 100 mg/100 mL to about 900 mg/100 mL of the formulation;
- wherein the pH of the solution ranges from about 2.5 to about 6.
Dependencies are inferred from the claim text.